A novel dry powder inhaler: Effect of device design on dispersion performance

International Journal of Pharmaceutics

Volumn 401, Issue 1-2, 2010, Pages 1-6

  Selvam, Parthiban ^a   McNair, Doug ^b   Truman, Randall ^c   Smyth, Hugh D C ^a  

^a UNIVERSITY OF TEXAS AT AUSTIN   (United States)

^b CERNER CORPORATION   (United States)

^c University of New Mexico   (United States)

Author keywords

Ciprofloxacin; Device resistance; Dry powder inhaler; Flutter; Next generation impactor

Indexed keywords

CIPROFLOXACIN;

AEROSOL; AIRFLOW; ARTICLE; DISPERSION; DRUG DELIVERY SYSTEM; FILM; GEOMETRY; PARTICLE SIZE; POWDER INHALER; PRIORITY JOURNAL;

ADMINISTRATION, INHALATION; AEROSOLS; ANTI-INFECTIVE AGENTS; CHEMISTRY, PHARMACEUTICAL; CIPROFLOXACIN; DRY POWDER INHALERS; EQUIPMENT DESIGN; SURFACE PROPERTIES;

EID: 78049266211     PISSN: 03785173     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijpharm.2010.07.056     Document Type: Article

References (30)

1. Adi H., et al. Controlled release antibiotics for dry powder lung delivery. Drug Dev. Ind. Pharm. 2009, 36:119-126.
2. Ashurst I., et al. Latest advances in the development of dry powder inhalers. Pharm. Sci. Technol. Today 2000, 3:246-256.
3. Ball D.J., et al. Deposition and pharmacokinetics of budesonide from the Miat Monodose inhaler, a simple dry powder device. Int. J. Pharm. 2002, 245:123-132.
4. Bisgaard H., et al. Fine particle mass from the Diskus inhaler and Turbuhaler inhaler in children with asthma. Eur. Respir. J.: Official J. Eur. Soc. Clin. Respir. Physiol. 1998, 11:1111-1115.
5. Clark A.R. Medical aerosol inhalers: past, present, and future. Aerosol Sci. Technol. 1995, 22:374-391.
6. Conley J., et al. Aerosol delivery of liposome-encapsulated ciprofloxacin: aerosol characterization and efficacy against Francisella tularensis infection in mice. Antimicrob. Agents Chemother. 1997, 41:1288-1292.
7. Connell B.S.H., Yue D.K.P. Flapping dynamics of a flag in a uniform stream. J. Fluid Mech. 2007, 581:33-67.
8. Crompton G.K. Dry powder inhalers: advantages and limitations. J. Aerosol Med.: Official J. Int. Soc. Aerosol Med. 1991, 4:151-156.
9. Donovan M., et al. Tunable dry powder inhalers: future or folly?. Respir. Drug Deliv. 2009, 1:189-200.
10. Fitzgeorge R.B., et al. Treatment of experimental legionnaires-disease by aerosol administration of rifampicin, ciprofloxacin, and erythromycin. Lancet 1986, 1:502-503.
11. French D.L., Edwards D.A., Niven R.W. The influence of formulation on emission, deaggregation and deposition of dry powders for inhalation. J. Aerosol Sci. 1996, 27:769-783.
12. Gallegos M. Flow Induced Flutter of Thin Elastic Films 2008, University of New Mexico, M.S. Albuquerque, NM.
13. Ganderton D.J., Kaseem N.M. Dry powder inhaler. Advances in Pharmaceutical Sciences 1992, Academic Press, London, pp. 165-191.
14. Geller D.E. Comparing clinical features of the nebulizer, metered-dose inhaler, and dry powder inhaler. Respir. Care 2005, 50:1313-1321. discussion 1321-1322.
15. Hickey A.J., et al. Factors influencing the dispersion of dry powders as aerosols. Pharm. Technol. 1994, 8:58-82.
16. Islam N., Gladki E. Dry powder inhalers (DPIs) - a review of device reliability and innovation. Int. J. Pharm. 2008, 360:1-11.
17. Louey M.D., Stewart P.J. Particle interactions involved in aerosol dispersion of ternary interactive mixtures. Pharm. Res. 2002, 19:1524-1531.
18. Meirovitch L., Ghosh D. Control of flutter in bridges. J. Eng. Mech. 1987, 113:720-736.
19. Moretti, P.M., 2003. Tension in fluttering flags. In Tenth International Congress on Sound and Vibration. Stockholm, Sweden.
20. Newman S.P., Busse W.W. Evolution of dry powder inhaler design, formulation, and performance. Respir. Med. 2002, 96:293-304.
21. Newman S.P. Dry powder inhalers for optimal drug delivery. Expert Opin. Biol. Ther. 2004, 4:23-33.
22. Njuguna J. Flutter prediction, suppression and control in aircraft composite wings as a design prerequisite: a survey. Struct. Control Health Monit. 2007, 14:715-758.
23. Smith I.J., Parry-Billings M. The inhalers of the future? A review of dry powder devices on the market today. Pulm. Pharm. Ther. 2003, 16:79-95.
24. Smyth H.D.C., Gallegos M., Truman R.C. A novel mechanism of dry powder inhaler dispersion: optimizing flow induced flutter. Respir. Drug Deliv. 2008, 3:877-880.
25. Smyth, H.D.C., Truman, R.C., 2008. Dry powder Inhaler with Aeroelastic dispersion mechanism, EP20070752039.
26. Srichana T., Martin G.P., Marriott C. Dry powder inhalers: the influence of device resistance and powder formulation on drug and lactose deposition in vitro. Eur. J. Pharm. Sci. 1998, 7:73-80.
27. Telko M.J., Hickey A.J. Dry powder inhaler formulation. Respir. Care 2005, 50:1209-1227.
28. Thorsson L., Edsbacker S., Conradson T. Lung deposition of budesonide from Turbuhaler is twice that from a pressurized metered-dose inhaler P-MDI. Eur. Respir. J. 1994, 7:1839-1844.
29. Waknine Y. FDA Approves Orphan Drug Status for Inhaled Ciprofloxacin for Cystic Fibrosis 2010, Medscape Today.
30. Zeng X.M., et al. Effects of particle size and adding sequence of fine lactose on the deposition of salbutamol sulphate from a dry powder formulation. Int. J. Pharm. 1999, 182:133-144.